Nitracrine
(Synonyms: 二胺硝吖啶) 目录号 : GC33400Nitracrine是一种已在临床上使用数年的抗肿瘤药物。
Cas No.:4533-39-5
Sample solution is provided at 25 µL, 10mM.
Nitracrine is an antitumor drug that has been used clinically for several years.
It is demonstrated during the reduction of ledakrin that a key metabolite, a compound with anadditional five-membered ring attaching to positions 1 and 9 of the acridine core and with the retained 9-aminoalkyl side chain, is formed in all the systems that are studied. It is determined that the reactive nitrogen atoms of this additional ring undergo further transformations resulting in the formation of a six-membered ring produced by the addition of a carbon atom to the dihydropyrazoloacridine ring. Furthermore, it is observed that positions 2 and 4 of ledakrin's acridine ring are susceptible to nucleophilic substitution as revealing by the studies with dithiothreitol. Additionally, although most products from the reduction of ledakrin are extremely unstable, 1-aminoacridinone, producing enzymatically and with dithiothreitol, exhibiting persistent stability under the studied conditions[1].
[1]. Gorlewska K, et al. Products of metabolic activation of the antitumor drug ledakrin (nitracrine) in vitro.
Cell experiment: | Six-week-old male rats are injected with 3-methylcholanthrene (4 mg/animal) for 3 days before decapitation. Livers are removed, homogenized in a homogenizer, and centrifuged for 30 min at 10000g.The activation of ledakrin with the microsomal fraction of rat liver is carried out in 0.16 M Trizma base buffer (pH 7.4). The incubation mixture consists of 125 mM nicotinamide, 100 mM glucose 6-phosphate, 10 mM NADPH, glucose-6-phosphate dehydrogenase (40 units), rat liver microsomes (5 mg/mL), andledakrin (1 mmol)[1]. |
References: [1]. Gorlewska K, et al. Products of metabolic activation of the antitumor drug ledakrin (nitracrine) in vitro. |
Cas No. | 4533-39-5 | SDF | |
别名 | 二胺硝吖啶 | ||
Canonical SMILES | O=[N+](C1=CC=CC2=NC3=CC=CC=C3C(NCCCN(C)C)=C21)[O-] | ||
分子式 | C18H20N4O2 | 分子量 | 324.38 |
溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 3.0828 mL | 15.414 mL | 30.828 mL |
5 mM | 0.6166 mL | 3.0828 mL | 6.1656 mL |
10 mM | 0.3083 mL | 1.5414 mL | 3.0828 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet